Annex 1 and What It Actually Means for Your Hiring Plan

Two years on from the revised Annex 1 taking effect, the hiring consequences are now clear enough to describe rather than predict. They were not distributed the way most sites expected.

Contamination control strategy created permanent roles, not project ones

Most sites treated the contamination control strategy as a documentation exercise with an end date. In practice it has become an ongoing function, and the sites that resourced it as a project are now recruiting permanently for work they assumed would be finished.

The demand landed in QA, not manufacturing

We expected more manufacturing and process hiring. What we saw instead was sustained growth in quality assurance headcount, particularly floor-facing QA with genuine aseptic technique assessment capability. That is a narrower pool than general pharmaceutical QA and it has not deepened.

Automation is now a quality argument

The emphasis on minimising intervention has made barrier and isolator technology a regulatory position rather than an efficiency one. Sites investing in it need automation engineers who understand GMP, and engineers who can hold both are genuinely scarce.

What we would advise

• Resource contamination control strategy as a standing capability, not a project team

• Recruit floor-facing QA earlier than your gap analysis suggests, because the lead time is longer than you think

• Treat GMP-literate automation engineers as a separate market from general automation, and pay accordingly

• Do not assume sterile experience transfers cleanly between solid dose and fill-finish sites